Adrenoleukodystrophy and related disorders

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 7, Issue 3, 2001, Pages 179-189

  Percy, Alan K ^a,b   Lane Rutledge, S ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Adrenoleukodystrophy; Peroxisomes; Phytanic acid; Very long chain fatty acids; X linked

Indexed keywords

ADRENOLEUKODYSTROPHY RELATED PROTEIN; BETA INTERFERON; CYCLOPHOSPHAMIDE; GENE PRODUCT; MEVINOLIN; THALIDOMIDE; UNCLASSIFIED DRUG;

ADRENOLEUKODYSTROPHY; CHONDRODYSPLASIA PUNCTATA; DIET THERAPY; GENE THERAPY; HUMAN; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PEROXISOME; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REFSUM DISEASE; REVIEW; X CHROMOSOMAL INHERITANCE; ZELLWEGER SYNDROME;

ADOLESCENT; ADRENOLEUKODYSTROPHY; ADULT; BRAIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PEROXISOMES;

EID: 0034843967     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrdd.1026     Document Type: Review

References (85)

1. X-linked adrenoleukodystrophy enigma: How does the ALD peroxisomal transporter mutation affect CNS glia?
2. Neonatal adrenoleukodystrophy
3. Pseudo infantile Refsum's disease: Catalase-deficient peroxisomal particles with partial deficiency of plasmalogen synthesis and oxidation of fatty acids
4. Rhizomelic chondrodysplasia punctata with isolated DHAP-AT deficiency
5. A familial syndrome of multiple congenital defects
6. Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata
7. An isoform of Pex5p, the human PTS1 receptor, is required for the import of PTS2 proteins into peroxisomes
8. Isolation of the human PEX12 gene, mutated in group 3 of the peroxisome biogenesis disorders
9. Deficiency of enzymes catalyzing the biosynthesis of glycerol-ether lipids in Zellweger syndrome. A new category of metabolic disease involving the absence of peroxisomes
10. A unified nomenclature for peroxisome biogenesis factors
11. Mutations in the adrenoleukodystrophy gene
12. Mutations in the PTS1 receptor gene, PXR1, define complementation group 2 of the peroxisome biogenesis disorders
13. Cognitive and brain magnetic resonance imaging findings in adrenomyeloneuropathy
14. Developmental delay and growth failure caused by a peroxisomal disorder, dihydroxyacetone-phosphate acyltransferase (DHAP-AT) deficiency
15. Mutational and protein analysis of patients and heterozygous women with X-linked adrenoleukodystrophy
16. Disruption of a PEX1-PEX6 interaction is the most common cause of the neurologic disorders Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease
17. Heredopathia atactica polyneuritiformis: Refsum's disease
18. Human adrenoleukodystrophy protein and related peroxisomal ABC transporters interact with the peroxisomal assembly protein PEX19p
19. Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome
20. Peroxisomal defects in neonatal-onset and X-linked adrenoleukodystrophies
21. A neurophysiological study of children with the cerebro-hepato-renal syndrome of Zellweger
22. Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy
23. Adrenomyeloneuropathy: A probable variant of adrenoleukodystrophy. I. Clinical and endocrinologic aspects
24. Isolated dihydroxyacetonephosphateacyl-transferase deficiency in rhizomelic chondrodysplasia punctata: Clinical presentation, metabolic and histological findings
25. Mutation in PEX16 is causal in the peroxisome-deficient Zellweger syndrome of complementation group D
26. A missense mutation in the ring finger motif of PEX2 protein disturbs the import of peroxisome targeting signal 1 (PTS1)-containing protein but not the PTS2-containing protein
27. Phytanoyl-CoA hydroxylase is not only deficient in classical Refsum disease but also in rhizomelic chondrodysplasia punctata
28. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene
29. Visual system abnormalities in adrenomyeloneuropathy
30. Polarizing inclusions in some organs of children with congenital peroxisomal diseases (Zellweger's, Refsum's, chondrodysplasia punctata (rhizomelic form), X-linked adrenoleukodystrophy)
31. MR findings in adult-onset adrenoleukodystrophy
32. Central nervous system malformations and white matter changes in pseudo-neonatal adrenoleukodystrophy
33. Determination of 30 X-linked adrenoleukodystrophy mutations, including 15 not previously described
34. Spectrum of mutations in the gene encoding the adrenoleukodystrophy protein
35. Treatment of adrenoleukodystrophy with bone marrow transplantation
36. Infantile Refsum disease: Gastrointestinal presentation of a peroxisomal disorder
37. X-linked adrenoleukodystrophy presenting as neurologically pure familial spastic paraparesis
38. MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders
39. Tumor necrosis factor-alpha and X-linked adrenoleukodystrophy
40. Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X-linked adrenoleukodystrophy and multiple sclerosis
41. X-linked adrenoleukodystrophy: The role of contrast-enhanced MR imaging in predicting disease progression
42. Identification of PAHX, a Refsum disease gene
43. Disturbances in bile acid metabolism of infants with the Zellweger (cerebro-hepato-renal) syndrome
44. Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups
45. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls
46. The cerebrohepatorenal (Zellweger) syndrome. Increased levels and impaired degradation of very-long-chain fatty, acids and their use in prenatal diagnosis
47. Therapy of X-linked adrenoleukodystrophy: Prognosis based upon age and MRI abnormality and plans for placebo-controlled trials
48. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy
49. Adrenoleukodystrophy: Phenotype, genetics, pathogenesis and therapy
50. Genotype-phenotype correlations in peroxisomal disorders
51. Dietary management of X-linked adrenoleukodystrophy
52. Identification of female carriers of adrenoleukodystrophy
53. Adrenoleukodystrophy: Survey of 303 cases: Biochemistry, diagnosis, and therapy
54. Rhizomelic chondrodysplasia punctata is a peroxisomal protein targeting disease caused by a non-functional PTS2 receptor
55. Phytanic acid oxidation: Normal activation and transport yet defective alpha-hydroxylation of phytanic acid in peroxisomes from Refsum disease and rhizomelic chondrodysplasia punctata
56. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages
57. Lovastatin therapy for X-linked adrenoleukodystrophy: Clinical and biochemical observations on 12 patients
58. Clinical approach to inherited peroxisomal disorders
59. A new peroxisomal disorder with enlarged peroxisomes and a specific deficiency of acyl-CoA oxidase (pseudo-neonatal adrenoleukodystrophy)
60. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy
61. Adreno-leukodystrophy. Similar ultrastructural changes in adrenal cortical and Schwann cells
62. Adrenomyeloneuropathy: A neuropathologic review featuring its noninflammatory myelopathy
63. Rhizomelic chondrodysplasia punctata is caused by deficiency of human PEX7, a homologue of the yeast PTS2 receptor
64. Proton MR spectroscopy of childhood adrenoleukodystrophy
65. Neurophysiologic follow-up of long-term dietary, treatment in adult-onset adrenoleukodystrophy
66. Hepatic peroxisomes are deficient in infantile Refsum disease: A cytochemical study of 4 cases
67. Adrenoleukodystrophy. A clinical and pathological study of 17 cases
68. Human peroxisomal 3-oxoacylcoenzyme A thiolase deficiency
69. Lignoceric acid is oxidized in the peroxisome: Implications for the Zellweger cerebro-hepatorenal syndrome and adrenoleukodystrophy
70. Adrenoleukodystrophy: Impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes
71. Refsum disease: A defect in the alpha-oxidation of phytanic acid in peroxisomes
72. Neurological disorders and phytanic acid metabolism
73. Gene therapy: Where are we?
74. Mutational analysis and genotype-phenotype correlation of 29 unrelated Japanese patients with X-linked adrenoleukodystrophy
75. Peroxisomal bifunctional protein deficiency revisited: Resolution of its true enzymatic and molecular basis
76. Infantile phytanic acid storage disease, a disorder of peroxisome biogenesis: A case report
77. Human alkyldihydroxyacetonephosphate synthase deficiency: A new peroxisomal disorder
78. Peroxisomal disorders: A review
79. Peroxisomal disorders: Clinical, biochemical, and molecular aspects
80. Identification of PEX10, the gene defective in complementation group 7 of the peroxisome-biogenesis disorders
81. Pharmacological induction of peroxisomes in peroxisome biogenesis disorders
82. The peroxisome biogenesis disorder group 4 gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the PTS1 receptor
83. Adrenoleukodystrophy protein enhances association of very long-chain acyl-coenzyme A synthetase with the peroxisome
84. Genomic structure and identification of 11 novel mutations of the PEX6 (peroxisome assembly factor-2) gene in patients with peroxisome biogenesis disorders
85. Prenatal diagnosis of peroxisome biogenesis disorders by means of immunofluorescence staining of cultured chorionic villous cells